Mutations in the MPL gene were only seen in patients with primary myelofibrosis (MF). Driver mutations do not appear to be correlated with thrombosis and leukemic transformation in myeloproliferative ...

Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact—a study of 784 patients from the Quebec MPN research group. Alisa Poullet; ...

1 Introduction. The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are a group of slowly progressing haematological malignancies primarily characterised by an overproduction of ...

Background: About 20,000 people are diagnosed with Myeloproliferative Neoplasms (MPNs) in the US each year, and almost 300,000 have the disease. Age, race, and gender can affect clinical outcomes.

With the intent of dissecting the molecular complexity of Philadelphia-negative myeloproliferative neoplasms (MPN), we designed a target enrichment panel to explore, using next-generation ...

BACKGROUND: Myeloproliferative neoplasms (MPN) are a group of chronic leukemias that are associated with pulmonary hypertension (PH), which has been associated with increased risk adverse outcomes.

Assessing risk factors for the development of pulmonary hypertension in patients with myeloproliferative neoplasms: A meta-analysis and meta-regression.. JCO 43 , e18594-e18594 (2025). DOI: ...

In addition to the plenary presentation, Dr. Gill will also present results from the University of Hong Kong’s Phase 2 trial (NCT05731245) evaluating ropeginterferon alfa-2b in pre-fibrotic primary ...

In its latest advisory dated May 30, 2025, the FSSAI highlighted a growing trend: the use of "100%" claims on food labels and promotional materials. What Is This "100%" Claim. Although the FSSAI ...

PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms. Business ... NQ=F Nasdaq 100 Jun 25 21,743.75-101.00 (-0.46%) BTC-USD Bitcoin USD ...

PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms ...

BURLINGTON, Mass.--(BUSINESS WIRE)--Jun 3, 2025--PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms ...